Wt1 Lamp Mrna Dc

4 trials 1 recruiting

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

1 Recruiting

3 Completed trials

1 Sponsors

1 Countries

Phase II

Phase II: 4

Sponsors using this IMP

Antwerp University Hospital 4

All trials

4 total

Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into platinum/pemetrexed-based first-line treatment for epithelioid m… Recruiting

2024-515293-27-00 Phase II 1 country Antwerp University Hospital
Adjuvant dendritic-cell immunotherapy plus temozolomide following surgery and chemoradiation in patients with newly diagnosed glioblastoma Ended

2024-515291-13-00 Phase II 1 country Antwerp University Hospital
Adjuvant dendritic cell immunotherapy complementing conventional therapy for pediatric patients with high-grade glioma and diffuse intrinsic… Ended

2024-515295-12-00 Phase II 1 country Antwerp University Hospital
First-line immunotherapy using Wilms’ tumor protein 1 (WT1)-targeted dendritic cell vaccinations for malignant pleural mesothelioma Ended

2024-517970-35-00 Phase II 1 country Antwerp University Hospital

Showing 1–4 of 4 trials

← All drugs A–Z